Clinical Trial

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Study acronym: Phoenix
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-08-20; most recent amendment 2024-08-09.
Status change: Recruiting → Active, Not Recruiting 2023-01-04
Status change: Not Yet Recruiting → Recruiting 2021-11-30
Trial Details
NCT Number NCT05021536
Lead Sponsor Amylyx Pharmaceuticals Inc.
Conditions Amyotrophic Lateral Sclerosis
Enrollment 664 participants
Start Date 2021-10-28
Primary Completion 2024-01-19 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2024-08-14